var data={"title":"Hyaluronate derivatives: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hyaluronate derivatives: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6318?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hyaluronate-derivatives-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hyaluronate derivatives: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179379\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amvisc;</li>\n      <li>Amvisc Plus;</li>\n      <li>Bionect;</li>\n      <li>Durolane;</li>\n      <li>Euflexxa;</li>\n      <li>Gel-One;</li>\n      <li>Gelsyn-3;</li>\n      <li>GenVisc 850;</li>\n      <li>Healon;</li>\n      <li>Healon GV;</li>\n      <li>Hyalgan;</li>\n      <li>HyGel [DSC];</li>\n      <li>Hylase Wound [DSC];</li>\n      <li>Hymovis;</li>\n      <li>Juvederm Ultra;</li>\n      <li>Juvederm Ultra Plus;</li>\n      <li>Juvederm Ultra Plus XC;</li>\n      <li>Juvederm Ultra XC;</li>\n      <li>Juvederm Voluma XC;</li>\n      <li>Monovisc;</li>\n      <li>Orthovisc;</li>\n      <li>Perlane;</li>\n      <li>Perlane-L;</li>\n      <li>Provisc;</li>\n      <li>Restylane;</li>\n      <li>Restylane Lyft;</li>\n      <li>Restylane Silk;</li>\n      <li>Restylane-L;</li>\n      <li>Supartz FX;</li>\n      <li>Supartz [DSC];</li>\n      <li>Synvisc;</li>\n      <li>Synvisc-One</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179380\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cystistat;</li>\n      <li>Durolane;</li>\n      <li>OrthoVisc;</li>\n      <li>Suplasyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179410\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Miscellaneous;</li>\n      <li>\n        Cosmetic Agent, Implant;</li>\n      <li>\n        Ophthalmic Agent, Viscoelastic;</li>\n      <li>\n        Skin and Mucous Membrane Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179383\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical aid:</b> Ophthalmic (Amvisc, Amvisc Plus, Provisc): Intraocular: Depends upon procedure (slowly introduce a sufficient quantity into eye)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoarthritis of the knee:</b> Intra-articular:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Durolane: Inject 60 mg (3 mL) once</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Euflexxa: Inject 20 mg (2 mL) once weekly for 3 weeks (total of 3 injections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel-One: Inject 30 mg (3 mL) once</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gelsyn-3: Inject 16.8 mg (2 mL) once weekly for 3 weeks (total of 3 injections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GenVisc 805, Supartz, Supartz FX: Inject 25 mg (2.5 mL) once weekly for 5 weeks (total of 5 injections); some patients may benefit from a total of 3 injections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hyalgan: Inject 20 mg (2 mL) once weekly for 5 weeks (total of 5 injections); some patients may benefit with a total of 3 injections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hymovis: Inject 24 mg (3 mL) once weekly for 2 weeks (total of 2 injections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monovisc: Inject 88 mg (4 mL) once</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orthovisc: Inject 30 mg (2 mL) once weekly for 3 to 4 weeks (total of 3 to 4 injections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synvisc: Inject 16 mg (2 mL) once weekly for 3 weeks (total of 3 injections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synvisc-One: Inject 48 mg (6 mL) once</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Visco-3: Inject 25 mg (2.5 mL) once weekly for 3 weeks (total of 3 injections)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Facial wrinkles/folds:</b> Intradermal:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <b>Note: </b>Formulations differ in terms of recommended injection depth: Juvederm (all formulations except Voluma XC), Restylane, Restylane Defyne, Restylane-L, and Restylane Refyne are intended for mid to deep intradermal injection; Perlane and Restylane Lyft are intended for injection into the deep dermis to superficial subcutis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm (all formulations except Voluma XC): Inject as required for cosmetic result; typical treatment regimen requires 1.6 to 1.7 mL/treatment site; typical volume for repeat treatment is 0.56 to 0.7 mL/treatment site; maximum: 20 mL/60 kg/year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Perlane, Restylane Lyft: Inject as required into deep dermis/superficial subcutis for cosmetic result; median total dose: 3 mL (Perlane); maximum: 6 mL per treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane, Restylane-L: Inject as required for cosmetic result; median total dose: 3 mL; maximum: 6 mL per treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Defyne: Inject as required for cosmetic result; typical treatment is generally ~1.4 mL/treatment site; typical repeat treatment is ~0.7 mL/treatment site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Refyne: Inject as required for cosmetic result; typical treatment is generally ~1.5 mL/treatment site; typical repeat treatment is ~1 mL/treatment site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cheek augmentation: </b>Subcutaneous/Supraperiosteal: Adults &gt;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvaderm Voluma XC: Inject as required for cosmetic result; typical treatment regimen requires small boluses of 0.1 to 0.2 mL over a large area to volumize and contour the cheek; an additional treatment may be needed to achieve the desired level of correction; maximum: 20 mL/60 kg/year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Lyft: Maximum: 6 mL per treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lip augmentation:</b> Submucosal: Adults &gt;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Ultra XC: Approximately 2.2 mL to the lips and perioral area; correct to 100% of desired volume effect (do not overcorrect); repeat treatment is generally 1.5 mL; maximum: 20 mL/60 kg/year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Volbella XC: Approximately 2.6 mL to the lips and perioral area; correct to 100% of desired volume effect (do not overcorrect); repeat treatment is generally 1.6 mL; maximum: 20 mL/60 kg/year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane, Restylane-L, Restylane Silk: Maximum: 1.5 mL per lip (upper or lower) per treatment session</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioral rhytids:</b> Intradermal: Adults &gt;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Silk: Maximum: 1 mL per correction per treatment session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Volbella XC: Refer to lip augmentation dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin ulcers and wounds:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bionect cream, gel: Apply a thin layer to clean and disinfected wound or ulcer 2 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hylase Wound gel: Apply liberally to ulcer cavity or wound and to surrounding areas once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Interstitial cystitis, refractory (off-label use):</b> Intravesical (off-label route): 40 mg in 50 mL saline intravesically (retain in bladder for at least 30 minutes) once weekly for 4 weeks, then monthly for up to 1 year in patients showing an initial response (Morales 1996)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179384\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46152040\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46152041\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179365\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, topical [sodium hyaluronate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bionect: 0.2% (25 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam, topical [sodium hyaluronate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bionect: 0.2% (113.4 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical [sodium hyaluronate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bionect: 0.2% (30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HyGel: 2.5% (10 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hylase Wound: 2.5% (75 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, gel, intra-articular [hyaluronic acid]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Durolane: 20 mg/mL (3 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, gel, intra-articular [cross-linked hyaluronate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel-One: 10 mg/mL (3 mL) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, gel, intradermal [hyaluronic acid]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Ultra: 24 mg/mL (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Ultra Plus: 24 mg/mL (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Ultra Plus XC: Hyaluronic acid 24 mg/mL and lidocaine 0.3% (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Ultra XC: Hyaluronic acid 24 mg/mL and lidocaine 0.3% (0.4 mL, 0.8 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Perlane: 20 mg/mL (1 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Perlane-L: Hyaluronic acid 20 mg/mL and lidocaine 0.3% (1 mL, 2 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane: 20 mg/mL (0.4 mL, 1 mL, 2 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane-L: Hyaluronic acid 20 mg/mL and lidocaine 0.3% (0.5 mL, 1 mL, 2 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Lyft: Hyaluronic acid 20 mg/mL and lidocaine 0.3% [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Silk: Hyaluronic acid 20 mg/mL and lidocaine 0.3% [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, gel, subcutaneous/supraperiosteal [cross-linked hyaluronic acid]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Voluma XC: Hyaluronic acid 20 mg/mL and lidocaine 0.3% [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, intra-articular [hyaluronan]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Monovisc: 88 mg/4 mL (4 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hymovis: 24 mg/3 mL (3 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orthovisc: 30 mg/2 mL (2 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, intra-articular [hylan polymers A and B]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synvisc-One: 8 mg/mL (6 mL) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synvisc: 8 mg/mL (2 mL) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, intra-articular [sodium hyaluronate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Euflexxa: 10 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gelsyn-3: 8.4 mg/mL (2 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GenVisc 850: 25 mg/2.5 mL (2.5 mL) [derived from or manufactured from bacterial source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hyalgan: 10 mg/mL (2 mL) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Supartz: 10 mg/mL (2.5 mL [DSC]) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Supartz FX: 25 mg/2.5 mL (2.5 mL) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Visco-3: 10 mg/mL (2.5 mL) [derived from or manufactured using an avian source]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, intraocular [sodium hyaluronate]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Amvisc: 12 mg/mL (0.5 mL, 0.8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Amvisc Plus: 16 mg/mL (0.5 mL, 0.8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Healon: 10 mg/mL (0.4 mL, 0.55 mL, 0.85 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Healon GV: 14 mg/mL (0.55 mL, 0.85 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Provisc: 10 mg/mL (0.4 mL, 0.55 mL, 0.85 mL) [contains natural rubber/natural latex in packaging]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179353\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179367\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intra-articular: Inject directly into the knee joint; do not inject extra-articularly or into the synovial capsule or tissues. Do not use disinfectants containing quaternary ammonium salts for skin cleansing prior to injection. Remove synovial fluid or effusion, if present, prior to injection. If used for bilateral treatment, use a separate syringe for each knee. Refer to manufacturer's labeling for additional instructions on injection technique.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intradermal/Submucosal/Subcutaneous/Supraperiosteal: Do not inject into a blood vessel. Following injection, slowly massage area so that it conforms to the contour of the surrounding tissue. May apply ice pack to injection site for a short period immediately after administration if treatment area swollen. Refer to manufacturer's labeling for additional instructions on injection technique. Prior to treatment, the patient should avoid taking aspirin, nonsteroidal anti-inflammatory medications, St. John's wort, or high doses of vitamin E supplements; these agents may increase bruising and bleeding at the injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm (all formulations except Voluma XC) is intended for mid-to-deep intradermal injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Voluma XC is intended for subcutaneous and/or supraperiosteal injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Ultra XC is also intended for submucosal injection (lip augmentation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Perlane is intended for injection into the deep dermis to superficial subcutis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane and Restylane-L are intended for mid-to-deep intradermal injection (facial wrinkles) or submucosal injection (lip augmentation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Defyne and Restylane Refyne are intended for mid-to-deep intradermal injection (facial wrinkles).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Lyft is intended for deep dermis to superficial subcutis (facial wrinkles) or subcutaneous and/or supraperiosteal (cheek augmentation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Restylane Silk is intended for mid to deep dermis (periorbital rhytids) or submucosal injection (lip augmentation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Allow to reach room temperature prior to use. Drug may become cloudy or form a slight precipitate after administration; clinical significance unknown, but cloudy or precipitated material should be removed by irrigation or aspiration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bionect products: Clean and disinfect wound prior to use (do not use quaternary ammonium salts due to potential for hyaluronic acid precipitation), and debride if necessary; apply a thin layer to wound or ulcer without extensive rubbing. After application, cover the area with a sterile gauze pad and if necessary, an elastic or compressive bandage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hylase Wound: Clean ulcer or wound with normal saline, remove excess moisture with dry gauze, then apply gel liberally to wound or ulcer and surrounding areas. After application, cover the area with a sterile nonstick gauze pad and adhesive tape/bandage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179366\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-articular injection:</b> Treatment of pain in osteoarthritis of the knee in patients who have failed nonpharmacologic treatment or simple analgesics (Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, OrthoVisc, Supartz, Supartz FX, Synvisc, Synvisc-One, Visco-3) or nonsteroidal anti-inflammatory drugs (NSAIDS) (Gel-One)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intradermal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm (all formulations except Volbella XC and Voluma XC), Perlane, Restylane, Restylane Defyne, Restylane Lyft, Restylane-L, Restylane Refyne: Correction of moderate to severe facial wrinkles or folds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Juvederm Volbella XC and Restylane Silk: Correction of perioral rhytids in adults &gt;21 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subcutaneous/supraperiosteal: </b>Juvederm Voluma XC, Restylane Lyft: Correction of age-related volume deficit (deep [subcutaneous and/or supraperiosteal] injection) for cheek augmentation in the mid-face in adults &gt;21 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic:</b> Surgical aid in cataract extraction (Amvisc, Amvisc Plus, Provisc); intraocular lens implantation (Amvisc, Amvisc Plus, Provisc); corneal transplant (Amvisc, Amvisc Plus); glaucoma filtration (Amvisc, Amvisc Plus); and retinal attachment surgery (Amvisc, Amvisc Plus)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Submucosal:</b> Lip augmentation in adults &gt;21 years (Restylane, Restylane-L, Restylane Silk, Juvederm Ultra XC, Juvederm Volbella XC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Topical cream, gel:</b> Management of skin ulcers and wounds (Bionect, Hylase Wound)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726035\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Refractory interstitial cystitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179417\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synvisc may be confused with Synagis</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179359\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined and type of local reactions may vary by formulation and site of application/injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin discoloration at injection site (intradermal, subcutaneous, submucosal 4% to 78%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (intradermal 14% to 28%; more common in older patients; intra-articular &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site (intradermal, subcutaneous, submucosal): Swelling (8% to 98%), tenderness (17% to 95%), erythema (11% to 93%), bruising (3% to 93%), induration (6% to 92%), pain (3% to 92%; most reports were mild and did not exceed 3 days postinjection), residual mass (3% to 90%), itching (10% to 47%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (intra-articular 1% to 25%), joint swelling (knee; intra-articular &le;14%), joint effusion (intra-articular &le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Swelling (intradermal 18% to 28%; more common in younger patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Presyncope (subcutaneous &le;5%), increased blood pressure (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (submucosal, subcutaneous, intramuscular, intra-articular &le;11%), dizziness (subcutaneous &le;5%), hyperesthesia (injection site; subcutaneous &le;5%), hypoesthesia (injection site; subcutaneous &le;5%), malaise (subcutaneous &le;5%), tingling in the lips (subcutaneous &le;5%), falling (1% to &le;4%), fatigue (1%), paresthesia (intra-articular 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperpigmentation (intradermal 9%; postinflammatory; in patients of African-American heritage and Fitzpatrick Skin Types IV, V, and VI), exfoliation of skin (submucosal 2% to 8%), cheilosis (subcutaneous &le;5%), fine wrinkling (subcutaneous &le;5%), local acneiform eruptions (subcutaneous &le;5%), local dryness (subcutaneous &le;5%), papule (injection site; subcutaneous &le;5%), rash at injection site (subcutaneous &le;5%), skin tightness (subcutaneous &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral herpes (subcutaneous &le;5%), toothache (intra-articular 4%), abdominal pain (1% to &le;4%), diarrhea (&le;4%), dyspepsia (1% to &le;4%), nausea (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (1% to &le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (intra-articular 2%), infection (intra-articular 1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (1% to 6%), injection site nodule (subcutaneous &le;5%), injection site numbness (subcutaneous &le;5%), local skin exfoliation (subcutaneous &le;5%), pain at injection site (intra-articular &le;5%), swelling at injection site (intra-articular &le;3%), infection (intradermal, subcutaneous, submucosal 1%; including abscess/necrosis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (intra-articular &le;8%), back pain (intra-articular &le;10%), puffiness of cheeks (upon waking up; subcutaneous &le;5%), leg pain (including discomfort 1% to &le;4%), connective tissue disease (intra-articular &le;4%), musculoskeletal disease (intra-articular &le;4%; including pain and discomfort), tendonitis (intra-articular 2%), localized osteoarthritis (intra-articular &le;2%), arthropathy (intra-articular &le;4%), joint stiffness (intra-articular &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Corneal edema, increased intraocular pressure (postoperative; transient), ophthalmic inflammation (postoperative; iritis, hypopyon)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (intra-articular 1% to 6%), nasopharyngitis (intra-articular 10%; submucosal 5%), bronchitis (1% to &le;4%), flu-like symptoms (1% to &le;4%), rhinitis (1% to &le;4%), sinusitis (1% to &le;4%), oropharyngeal pain (intra-articular 2%), respiratory tract infection (intra-articular 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Laceration (injection site; subcutaneous &le;5%), soft tissue injury (lips; subcutaneous &le;5%), wound (subcutaneous &le;5%), accidental injury (1% to &le;4%), fever (intra-articular 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abscess, acne vulgaris, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, application site reaction (implant migration), atrophy at injection site, bacterial infection, blindness, blurred vision, bruise, burning sensation, bursitis, capillary fragility, central nervous system disease, cerebrovascular accident, cutaneous nodule, cystitis, dermatitis, depression, dislocation (joint), drainage, dyspnea, edema, erythema, eyelid edema, eye pain, eye swelling, facial swelling, feeling of heaviness, fistula, gouty arthritis, granuloma, hemarthrosis, hematoma, herpetic lesion, hypersensitivity reaction, hypertension, hypoesthesia, hypotension, increased serum glucose, injection site infection (abscess/necrosis), increased serum ALT, inflammation, injection site ischemia, injection site numbness, injection site scarring, keloids, leukocytosis, metallic taste, mouth edema, muscle spasm (knee), myalgia, myasthenia, neck pain, nervousness, neuralgia, osteoarthritis, peripheral edema, popliteal cyst, pruritic rash, pruritus, red face, respiratory difficulty, rhinorrhea, sensation of cold (knee), sensory disturbance, skin blister, skin or other tissue necrosis, skin rash, sore throat, subcutaneous nodule, swelling of extremities, syncope, synovitis (knee), telangiectasia, thrombocytopenia (rare), tissue necrosis, urticaria, vasodepressor syncope, vertebral disk disease (protrusion), viral infection, visual disturbance, vomiting, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179370\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hyaluronate or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intradermal/Submucosal:</b> Additional contraindications include history of anaphylaxis or presence of multiple severe allergies (Juvederm [all formulations], Perlane, Restylane, Restylane Defyne, Restylane Lyft, Restylane Refyne, Restylane Silk, Restylane-L); bleeding disorders (Perlane, Restylane, Restylane Lyft, Restylane Silk, Restylane-L); history of hypersensitivity to gram-positive bacterial proteins (Juvederm [all formulations], Perlane, Restylane, Restylane Defyne, Restylane Lyft, Restylane Refyne, Restylane Silk, Restylane-L), or local anesthetics of the amide type, such as lidocaine (Juvederm Ultra XC, Juvederm Ultra Plus XC, Juvederm Volbella XC, Juvederm Vollure XC, Restylane Defyne, Restylane Lyft, Restylane Refyne, Restylane Silk); implantation/injection into sites other than the anatomical spaces recommended per labeling (Perlane, Restylane, Restylane Silk, Restylane-L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-articular:</b> Additional contraindications include knee joint infections or infections or skin diseases at the site of injection (Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, OrthoVisc, Supartz, Supartz FX, Synvisc, Synvisc-One, Visco-3); hypersensitivity to gram-positive bacterial proteins (Hymovis, Monovisc, Orthovisc); systemic bleeding disorders (Monovisc)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraocular:</b> There are no contraindications in the manufacturer's labeling (Amvisc, Amvisc Plus, Provisc).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subcutaneous/Supraperiosteal:</b> Additional contraindications include history of anaphylaxis or history or presence of multiple severe allergies (Juvederm Voluma XC, Restylane Lyft); patients with a history of allergies to gram-positive bacterial proteins or lidocaine (Juvederm Voluma XC, Restylane Lyft).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179356\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection (gel):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- May be administered by intradermal (Juvederm [all formulations except Voluma XC], Perlane, Restylane, Restylane Defyne, Restylane Lyft, Restylane Refyne, Restylane Silk), submucosal (Restylane, Restylane Silk), or subcutaneous and/or supraperiosteal (Juvederm Voluma XC, Restylane Lyft) injection. Treatment may result in bruising/bleeding; use caution in patients with bleeding disorders and patients receiving or recently exposed (&le;3 weeks) to thrombolytics, anticoagulants, platelet inhibitors, or NSAIDs. Do not inject into site of active inflammation (skin eruptions such as cysts, pimples, rashes, or hives) or infection. Injection into a blood vessel may cause localized superficial necrosis or may cause occlusion and lead to embolism, ischemia, or infarction. Symptoms of vascular occlusion or embolization (eg, pain disproportionate to the procedure or remote from the injection site, immediate blanching extending beyond the injected area, dusky or reticular-appearing tissue) require intervention. Do not use in vascular-rich areas, such as glabella and nose; vascular embolization/ocular vessel occlusion, such as blindness, and brain vessel occlusion resulting in cerebral infarction have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms, including changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Use of Juvederm in patients susceptible to keloid formation, hypertrophic scarring, or pigmentation disorders has not been studied; use cautiously. Following use of Perlane, Restylane, Restylane Lyft and Restylane Silk, hyperpigmentation may occur at the injection site and may last for &le;6 weeks after treatment; keloid formation may also occur. Use caution in patients receiving immunosuppressive treatment. Use in patients with prior herpetic eruption may result in reactivation. Delayed inflammatory papules may result from injections, necessitating evaluation and treatment as soft tissue infection. If laser treatment, chemical peeling, or any other procedure based on an active dermal response is considered after treatment, there is a risk of acute inflammatory reaction at the injection site if performed following intradermal treatment and before the skin has healed completely. The safety of treatment with concomitant dermal therapies such as epilation, UV irradiation, or laser, mechanical, or chemical peeling procedures has not been evaluated. Patient must avoid exposure to ultraviolet rays (sun and UV lamp) or severe cold until swelling and redness is resolved. Treatment site reactions usually improve in &le;7 days (nasolabial folds), &lt;18 days (lips), or &lt;4 weeks (cheek augmentation). Strenuous exercise and ethanol consumption should be avoided for 24 hours following use. Supplemental &quot;touch up&quot; treatments may be required. Use of larger than recommended volumes per injection result in an increase in adverse events; if larger amounts are needed, follow-up treatment sessions are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection (gel, solution): Intra-articular: Not for use in infected joints; do not use disinfectants containing quaternary ammonium salts for skin preparation (may cause precipitation of hyaluronate). Remove synovial fluid or effusion, if present, prior to injection; do not use in cases of severe intra-articular effusion. Do not inject intravascularly, extra-articularly, or into synovium. Use with caution if venous or lymphatic stasis is present in the leg. Transient increases in reddening or inflammation, pain, or sensation of heat may occur after injection into the knee in patients with inflammatory osteoarthritis. Avoid strenuous or prolonged weight bearing activities for 48 hours after injection. Some products are produced from avian sources; use with caution in patients with hypersensitivity to avian proteins, feathers, or egg products. Use Gel-One with caution in patients allergic to cinnamon. Use Durolane with caution in patients with preexisting chondrocalcinosis; may cause acute attack.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Some products may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic: Do not overfill the anterior chamber. Postoperative increases in intraocular pressure have occurred following use of sodium hyaluronate; remove from the anterior chamber at the end of surgery and monitor intraocular pressure closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Topical: Bionect products (cream, gel): Do not use disinfectants containing quaternary ammonium salts for skin preparation (may cause precipitation of hyaluronate).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate patient selection: Juvederm Voluma XC: Safety for use in patients &lt;35 years or &gt;65 years of age or with very thin skin in the mid-face region has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Restylane Defyne, Restylane Refyne: Do not inject in a site that has been treated with a permanent implant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Restylane Lyft: Safety and effectiveness for treatment beyond one year has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299452\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179360\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8643&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3423543\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Safety for use in pregnant women has not been established. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20614018\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if hyaluronic acid derivatives are present in breast milk. The manufacturers recommend that caution be exercised when administering to a breastfeeding woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179363\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure (ophthalmic formulations); signs and symptoms of excess local inflammation or infection (intradermal formulations)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179355\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium hyaluronate is a biological polysaccharide which is distributed widely in the extracellular matrix of connective tissue in man (vitreous and aqueous humor of the eye, synovial fluid, skin, and umbilical cord). Sodium hyaluronate and its derivatives form a viscoelastic solution in water (at physiological pH and ionic strength) which makes it suitable for aqueous and vitreous humor in ophthalmic surgery, and functions as a tissue and/or joint lubricant which plays an important role in modulating the interactions between adjacent tissues. Intradermal injection may decrease the depth of facial wrinkles. Transcutaneous injection for lip augmentation may correct perioral rhytids. Subcutaneous and/or supraperiosteal injection for cheek augmentation may correct age-related volume deficit. In the topical management of wounds and ulcers, sodium hyaluronate protects the skin against friction and abrasion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179369\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Intravitreous injection: Diffusion occurs slowly </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Ophthalmic: Via Canal of Schlemm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179371\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Bionect External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2% (25 g): $164.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Bionect External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2% (113.4 g): $992.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Bionect External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2% (100 g): $936.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Perlane Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $351.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Perlane-L Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $351.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/2 mL (2 mL): $632.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Restylane Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $319.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Restylane-L Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.5 mL (0.5 mL): $210.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $319.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/2 mL (2 mL): $574.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Hylira External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (340 g): $87.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe</b> (Durolane Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/3 mL (3 mL): $1,170.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amvisc Intraocular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/mL (0.8 mL): $151.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Amvisc Plus Intraocular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg/mL (0.8 mL): $182.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Euflexxa Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/2 mL (2 mL): $407.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Gelsyn-3 Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16.8 mg/2 mL (2 mL): $414.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Hymovis Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mg/3 mL (3 mL): $523.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Monovisc Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mg/4 mL (4 mL): $1,554.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (OrthoVisc Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/2 mL (2 mL): $520.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Supartz FX Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/2.5 mL (2.5 mL): $276.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Synvisc Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg/2 mL (2 mL): $507.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Synvisc One Intra-articular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">48 mg/6 mL (6 mL): $1,522.58</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179372\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adant Dispo (ID);</li>\n      <li>Amvisc (NL, PL);</li>\n      <li>Aragan (KR);</li>\n      <li>Aragan Plus (MY);</li>\n      <li>Artz (CN);</li>\n      <li>Atri (KR);</li>\n      <li>Biolon (IL, KR);</li>\n      <li>Curiosin (HU);</li>\n      <li>Duovisc (PH);</li>\n      <li>Durolane (AU, DE, FR, GB, ID, IT, PL);</li>\n      <li>Eyecon (IL);</li>\n      <li>Gengigel (MY);</li>\n      <li>Go-On (PH);</li>\n      <li>Halubone (KR);</li>\n      <li>Healon (CO, EC, HU, IN, LU, PK, TW, ZA);</li>\n      <li>Healon GV (ZA);</li>\n      <li>Healonid (AT, FR);</li>\n      <li>Helo (BD);</li>\n      <li>Hialid (ID, PH);</li>\n      <li>Hyal (MY);</li>\n      <li>Hyal Forte (KR);</li>\n      <li>Hyalein (JP);</li>\n      <li>Hyalgan (AT, BE, BG, BH, CY, CZ, DK, ES, FI, FR, HR, HU, IE, IS, IT, LB, LT, LU, LV, MT, PL, RO, SA, SI, SK, TR, VN);</li>\n      <li>Hyalgun (BD);</li>\n      <li>Hyaludrop (KR);</li>\n      <li>Hyfresh (QA);</li>\n      <li>Hylo-Care (QA);</li>\n      <li>Hylo-Comod (DE);</li>\n      <li>Hylo-COMOD (QA);</li>\n      <li>Hyronate (BD);</li>\n      <li>Hyruan (KR);</li>\n      <li>IAL (ID, MY);</li>\n      <li>Iolvisc (LU);</li>\n      <li>Kynex (KR);</li>\n      <li>Lacure (KR);</li>\n      <li>Laservis (DE, MY);</li>\n      <li>Lghyal (IN);</li>\n      <li>Osflex (ID);</li>\n      <li>Oxyal (AE);</li>\n      <li>Provisc (LU, ZA);</li>\n      <li>Suplasyn (DE, ID);</li>\n      <li>Synvisc (AE, AR, AU, BR, CH, CR, DO, EC, GB, GT, HK, HN, IE, JP, MX, NI, NZ, PA, PE, PH, PL, PY, SE, SG, SV, TH, UY, VE);</li>\n      <li>Synvisc One (CR, DO, GT, HK, HN, NI, PA, SG, SV, TH);</li>\n      <li>Synvisc-One (PH);</li>\n      <li>Toptear (GT);</li>\n      <li>Viscoseal (DE, MY);</li>\n      <li>Visiol (MY);</li>\n      <li>Vivial (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Constantinides C, Manousakas T, Nikolopoulos P, et al, &ldquo;Prevention of Recurrent Bacterial Cystitis by Intravesical Administration of Hyaluronic Acid: A Pilot Study,&rdquo; <i>BJU Int</i>, 2004, 93(9):1262-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronate-derivatives-drug-information/abstract-text/15180619/pubmed\" target=\"_blank\" id=\"15180619\">15180619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durolane (sodium hyaluronate) [prescribing information]. Durham, NC: Bioventus; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gel-One (cross-linked hyaluronate) [prescribing information]. Tokyo, Japan: Seikagaku Corporation; May 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gelsyn-3 (sodium hyaluronate) [prescribing information]. Durham. MC: Bioventus; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GenVisc 850 (sodium hyaluronate) [prescribing information]. Doylestown, PA: OrthogenRx Inc; no date.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hymovis (hyaluronic acid derivative) [prescribing information]. Parsippany, NJ: Fidia Pharma; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iavazzo C, Athanasiou S, Pitsouni E, &ldquo;Hyaluronic Acid: An Effective Alternative Treatment of Interstitial Cystitis, Recurrent Urinary Tract Infections, and Hemorrhagic Cystitis?,&rdquo; <i>Eur Urol</i>, 2007, 51(6):1534-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronate-derivatives-drug-information/abstract-text/17383810/pubmed\" target=\"_blank\" id=\"17383810\">17383810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juvederm Ultra XC (hyaluronic acid) [prescribing information]. 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juvederm Volbella XC (cross-linked hyaluronic acid) [prescribing information]. Irvine, CA: Allergan; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juvederm Vollure XC (cross-linked hyaluronic acid) [prescribing information]. Irvine, CA: Allergan; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juvederm Voluma XC (cross-linked hyaluronic acid) [prescribing information]. Goleta, CA: Allergan; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipovac M, Kurz C, Reithmayr F, et al, &ldquo;Prevention of Recurrent Bacterial Urinary Tract Infections by Intravesical Instillation of Hyaluronic Acid,&rdquo; <i>Int J Gynaecol Obstet</i>, 2007, 96(3):192-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronate-derivatives-drug-information/abstract-text/17280667/pubmed\" target=\"_blank\" id=\"17280667\">17280667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monovisc (hyaluronan) [prescribing information]. Bedford, MA: Anika Therapeutics Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morales A, Emerson L, Nickel JC, et al, &ldquo;Intravesical Hyaluronic Acid in the Treatment of Refractory Interstitial Cystitis,&rdquo; <i>J Urol,</i>, 1996, 156(1):45-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hyaluronate-derivatives-drug-information/abstract-text/8648835/pubmed\" target=\"_blank\" id=\"8648835\">8648835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restylane Defyne (hyaluronic acid) [prescribing information]. Fort Worth, TX: Galderma Laboratories; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restylane-L (hyaluronic acid) [prescribing information]. Uppsala, Sweden: Q-Med AB; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restylane Lyft (hyaluronate with lidocaine) [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restylane Refyne (hyaluronic acid) [prescribing information]. Fort Worth, TX: Galderma Laboratories; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restylane Silk (hyaluronic acid) [prescribing information].Bridgewater, NJ: Medicis; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Supartz FX (sodium hyaluronate) [prescribing information]. Durham, NC: Bioventus; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visco-3 (sodium hyaluronate) [prescribing information]. Warsaw, IN: Zimmer; received April 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8643 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F179379\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F179380\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F179410\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F179383\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F179384\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46152040\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46152041\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179365\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F179353\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F179367\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F179366\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726035\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F179417\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179359\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179370\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179356\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299452\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F179360\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3423543\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20614018\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F179363\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179355\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F179369\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F179371\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F179372\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8643|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hyaluronate-derivatives-patient-drug-information\" class=\"drug drug_patient\">Hyaluronate derivatives: Patient drug information</a></li></ul></div></div>","javascript":null}